Recent Updates — JSPR
Jasper Therapeutics announced the completion of enrollment for the IgA nephropathy (IgAN) cohort within its Phase 2 basket study evaluating vensobafusp alfa. The company expects to report initial interim data from this cohort by year-end 2026. Additionally, Jasper has accelerated the initiation of an expansion cohort for focal segmental glomerulosclerosis (FSGS), with the first patient anticipated to be dosed in the first quarter of 2027. A total of 18 patients were enrolled across three induction and maintenance dosing cohorts in stage 1 to assess safety, tolerability, and initial efficacy. Jasper Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for immune-mediated diseases.
Jasper Therapeutics has commenced a tender offer to purchase all outstanding warrants at $0.324 in cash per warrant, without interest. As of October 6, 2026, there were 12,345,707 warrants outstanding, representing potential dilution if exercised at the $2.92 strike price. The company expects to pay approximately $4.0 million from cash on hand if all warrants are tendered. The offer is open until November 6, 2026, and is not conditioned on a minimum number of tenders. Warrants retired in this transaction will be cancelled. Jasper Therapeutics operates as a clinical-stage biotechnology company focused on developing innovative therapies for immune-mediated diseases.
Jasper Therapeutics, Inc. filed an amendment to its Current Report on Form 8-K/A to include the audited financial statements of Kira Pharmaceuticals and unaudited pro forma condensed combined financial information following the completion of Jasper's acquisition of Kira on July 16, 2026. The transaction involved Kira merging into a wholly owned subsidiary of Jasper, with Kira shareholders receiving shares of Jasper common stock and non-voting convertible preferred stock. Concurrently, Jasper completed a private placement financing through the sale of approximately 4.7 million shares of non-voting convertible preferred stock for gross proceeds of $132 million. The pro forma financials reflect the merger, the concurrent private placement, the distribution of contingent value rights, and the Mirador License Agreement. Jasper Therapeutics, Inc. operates in the biotechnology industry, focusing on the discovery and development of novel therapeutics.
Jasper Therapeutics, Inc. reported that Chief Financial Officer Herb Cross resigned effective October 9, 2026, to pursue other professional endeavors. The Board appointed President and CEO Jeet Mahal as interim Principal Financial Officer, Vice President of Finance Rick Ruiz as interim Principal Accounting Officer, and COO Matthew Ros as interim Corporate Secretary. Mr. Ruiz will retain his current base salary of $364,000 per year and remains eligible for equity awards but received no new grants in connection with these interim appointments. Jasper Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare genetic diseases.
Jasper Therapeutics confirms that holders of its common stock as of the July 16, 2026 closing date of the Kira Pharmaceuticals acquisition are entitled to one contractual contingent value right (CVR) per share. Each CVR entitles the holder to a pro rata portion of $30 million if the FDA issues a Priority Review Voucher for briquilimab on or before December 31, 2028. The rights are non-transferable and unregistered. Jasper Therapeutics operates in the biotechnology industry.
On July 16, 2026, Jasper Therapeutics, Inc. completed the acquisition of Kira Pharmaceuticals through a merger agreement. The transaction involved the issuance of 5,195,009 shares of voting common stock and 4,644,977 shares of non-voting convertible preferred stock to Kira shareholders. Concurrently, Jasper completed a $132 million private placement (PIPE) involving the sale of approximately 4.7 million shares of preferred stock. The merger includes a contingent value right (CVR) agreement providing an aggregate $30 million milestone payment if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028. Jasper appointed Matthew Ros as Chief Operating Officer and Patrick Crutcher to the Board. Jasper Therapeutics is a biotechnology company developing immunologically-driven therapeutics.